Janssen, from Johnson & Johnson group, signed a partnership with MATWIN. This pharmaceutical laboratory committed to the research of innovative drugs in particular for onco- hematology indications is now a MATWIN industrial partner.
“This partnership fits perfectly with the open-innovation approach we are already leading to develop translational research and reduce the deadlines for the innovations to reach the patients. ” explains Emmanuelle Quilès, Janssen France president. “Beyond academic, fundamental collaborations and private partnerships already active, joining MATWIN is a great way to see and access early cancer research projects and therefore get every chance to answer unmet medical needs as fast as possible.”
